Dianthus Therapeutics, Inc.
General ticker "DNTH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $869.8M (TTM average)
Dianthus Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 2.0%: low 42.31$, high 44.04$
Factors to consider:
- Total employees count: 53 as of 2023
- Current price 31.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [13.14$, 31.76$]
- 2025-12-31 to 2026-12-31 estimated range: [10.31$, 25.65$]
Short-term DNTH quotes
Long-term DNTH plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $6.42MM | $2.83MM | $6.24MM |
| Operating Expenses | $36.12MM | $51.00MM | $108.10MM |
| Operating Income | $-29.70MM | $-48.17MM | $-101.86MM |
| Non-Operating Income | $1.23MM | $4.62MM | $16.89MM |
| R&D Expense | $29.38MM | $32.84MM | $83.11MM |
| Income(Loss) | $-28.48MM | $-43.55MM | $-84.97MM |
| Profit(Loss)* | $-28.48MM | $-43.55MM | $-84.97MM |
| Stockholders Equity | $73.66MM | $168.87MM | $352.48MM |
| Assets | $83.11MM | $179.41MM | $374.01MM |
| Operating Cash Flow | $-29.07MM | $-36.86MM | $-78.18MM |
| Capital expenditure | $0.14MM | $0.11MM | $0.10MM |
| Investing Cash Flow | $-59.82MM | $20.25MM | $-286.81MM |
| Financing Cash Flow | $96.68MM | $133.57MM | $255.62MM |
| Earnings Per Share** | $-7.60 | $-8.45 | $-2.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.